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Abstract
Background: The hands of the medical staff play an important role in transmission of pathogens in the health care
environment. Hand hygiene is efficient, easy to perform and cost-effective. Safety, tolerability and acceptance of
hand hygiene preparations play a major role in hand hygiene compliance, and apply, in particular, to formulations
with high anti-viral activity.
Aim: Clinical trial to evaluate the safety and tolerability of different virucidal hand rubs.
Methods: In a randomized, double-blind, four-period cross-over trial, healthy volunteers received three different
virucidal hand rubs (P1-P3) and a reference product (R) in randomized sequence over a period of 4 days each with
a washout period. The primary endpoint was skin barrier function measured by transepidermal water loss (TEWL)
after application.
Results: Twenty-two subjects (seven male, 15 female; median age 25, range 21–54) were randomized and started
at least one period. TEWL was 22.5; 95 %-confidence interval (CI): 19.6-25.4 after P1, 16.3; 13.5–19.1 after P2, 16.4;
13.4–19.3 after P3, and 24.0; 21.1–27.0 after R; p < 0.0001. The percentage of subjects experiencing at least one
adverse event (AE) was 86 % with P1, 25 % with P2, 89 % with P3 and 56 % with R. The majority of AEs were skin
reactions classified as of mild severity. No serious AEs were observed.
Conclusions: Results were inconsistent. The number of AEs was higher than expected for all products. In summary,
there is room for improvement both for hand rub development and the scientific approaches taken to practically
and reproducibly evaluate hand rub safety and tolerability.
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Background
The hands of the medical staff play an important role in
the transmission of pathogens in the health care environ-
ment. In the EU, approximately 4,100,000 patients are
estimated to acquire a healthcare-associated infection
every year [1]. Hand disinfection with an alcohol-based
hand rub is therefore the most important measure to
avoid hospital-acquired infections. Not only is it a key
parameter for patient safety, but also an important
component of the medical staff ’s workplace health
and safety.
In practice, the hands are not disinfected frequently
enough; various investigations have shown that hand
sanitizers are only used in every second to third
situation where actually necessary [2]. However, only
consistent hand hygiene protects patients and staff
reliably against transmission of clinical pathogens.
Factors influencing compliance with hand hygiene are
manifold and include medical staff workload, occupancy
rates, education and knowledge. The accessibility of
hand rubs is also an important factor.
Furthermore, the safety, tolerability and acceptance of
hand hygiene preparations impacts on compliance. In
Germany, hand rub is classified as a drug, approval of
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which includes evaluation for efficacy, safety and toler-
ability. Nonetheless, few systematic scientific trials are
available on the safety and tolerability of hand rubs. In
particular, comparative data are missing for different
preparations and their composition. The results obtained
in this work on the safety and tolerability of different vi-
rucidal hand rubs should provide important information
to optimize their safety and tolerability.
With their distinctive environmental stability and easy
transmissibility, viruses without capsids like adeno- and
norovirus pose a special challenge for the composition
of hand rubs [3–5]. Norovirus outbreaks in the health
service typically not only lead to illness in patients, but
also in staff, often resulting in an acute bottleneck in
medical and nursing care and the need for extra nursing
staff [6].
For effective hand hygiene against non-enveloped vi-
ruses it is recommended to use virucidal hand rubs that
either contain special alcohol compositions or are sup-
plemented with phosphoric acid. In practice, healthcare
workers often report impaired tolerability and poor com-
pliance with hand hygiene when using virucidal hand
rubs. For this reason, virucidal hand rubs appeared to be
especially suitable for safety and tolerability testing.
Methods
Study design
In a randomized, double-blind, four-period cross-over
trial, healthy volunteers applied three different virucidal
hand rubs in four intervention periods: P1 = Ethanol
(100 %) 45 g, 1-Propanol (Ph.Eur.) 18 g (Softa-Man®
acute, B. Braun Melsungen AG), P2 = Ethanol (99 %)
95 g (Sterillium® virugard, Bode Chemie Hamburg
GmbH), P3 = Ethanol (96 %) 57,6 g, 1-Propanol (Ph.Eur.)
10 g (Manorapid® Synergy, Antiseptica GmbH) and a ref-
erence product R = Ethanol (100 %) 45 g, 1-Propanol
(Ph.Eur.) 18 g (Softa-Man® pure, B. Braun Melsungen
AG). Volunteers were randomized between the four
intervention sequences R/P1/P3/P2, P1/P2/R/P3, P2/P3/
P1/R, and P3/R/P2/P1. To simulate regular hand hy-
giene in practice, the subjects had to carry out repetitive
hygienic hand disinfections. Each intervention period
lasted 4 days, on which the subjects had to apply a total of
90 mL virucidal hand rub within 90 min (approx. 30 times
3 mL of hand rub). To exclude a carry-over effect, each
interventional phase was interrupted by an investigation-
free washout period of 10 days.
Inclusion and exclusion criteria
Subjects were recruited from students of the Medical
Center, University of Freiburg, and nursing students of
the Freiburg Academy of Medical Professions. Inclusion
criteria were subject’s written informed consent, age >
18 years; legal capacity; healthy in body and mind and
not under medical treatment at the time of inclusion.
Exclusion criteria were simultaneous participation in
other interventional trials or within the last 30 days;
known or persistent abuse of medication, drugs or alco-
hol, relationship of dependence with the sponsor or the
investigator, dermatitis of any aetiology (e.g. hand ec-
zema, actinic dermatitis (hands), atopic dermatitis);
known allergy to one of the substances under investiga-
tion; regular contact with cleaning agents or rubs, or
regular immersion of hands in fluid (e.g. nursing care,
cleaning company, gastronomy, etc.).
Endpoints
The primary endpoint was the skin barrier function
measured by TEWL in g/hm2 with the Tewameter®
TM210 (Company Courage and Khazaka, Cologne).
The following secondary endpoints were assessed: Skin
hydration measured by corneometry with the Corne-
ometer CM 820 (Company Courage and Khazaka, Co-
logne) and skin status clinically evaluated according to
the European Society of Contact Dermatitis (ESCD)
guideline [7]. The sum of scores 0 = no signs, 0.5, 1, 2,
or 3 =marked signs assigned to signs of erythema,
roughness/contour, scaling, oedema and fissures was cal-
culated, whereby a sum score ≥3 was regarded as moder-
ate or critical. Satisfaction was assessed by a questionnaire
filled out by the subjects. AEs and serious AEs were coded
by the Medical Dictionary for Regulatory Activities (Med-
DRA), Version 13.0.
All the endpoints were assessed at the end of each 4-day
application period. TEWL and corneometry measure-
ments were also taken at baseline before each application
period. AEs were recorded over the whole study period
and assigned to the respective application period if they
occurred before application of the next agent.
Statistics
Because there was no knowledge of the safety or toler-
ability of the investigational products, this study was
planned as a pilot trial without formal sample size calcu-
lation. It was planned to include 20 subjects.
All the analyses were performed in the safety popula-
tion, including subjects who had started treatment in at
least one period. The endpoints TEWL and corneometry
were additionally analysed in the per-protocol popula-
tion (PP), including only subjects having completed all
four intervention periods and for whom the endpoints
were assessed.
TEWL and corneometry were analysed in linear
models including ‘agent’, ‘period’, ‘randomized sequence’
and ‘baseline measurement’ as fixed effects, and ‘subject
within sequence’ as random effect. From these models,
mean values per agent were estimated with 95 % CI.
And the effects of the different agents were estimated as
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differences between agents with 95 % CI and tested with




Twenty-two subjects (seven male, 15 female, median age
25, range 21–54) were randomized. Figure 1 shows the
randomized allocation to the different intervention se-
quences and the flow of the subjects through the four
intervention periods in CONSORT diagram. All subjects
started at least one intervention period and were thus
included in the safety population for at least one agent.
The primary endpoint was available for 21 subjects after
at least one intervention period. Twenty-one subjects
started application of P1 (primary endpoint available for
Fig. 1 Trial Flow
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n = 18), 20 subjects started P2 (primary endpoint avail-
able for n = 20), 18 subjects started P3 (primary endpoint
available for n = 18), and 18 subjects started R (primary
endpoint available for n = 17). Results are presented for
the safety population. In general, results for the PP
population (n = 14) did not differ from those of the
safety population
Primary endpoint—TEWL
Table 1 shows the results of the post-intervention TEWL
measurements by intervention period and agent (mean
and standard deviation, SD). The mean results of post-
intervention TEWL measurements using the different
agents were 22.5; 95 %-CI: 19.6–25.4 after P1, 16.3;
95 %-CI: 13.5–19.1 after P2, 16.4; 95 %-CI: 13.4–19.3
after P3, and 24.0; 95 %-CI 21.1–27.0 after R; test of dif-
ference between agents P < 0.0001. The differences in
TEWL between agents with 95 % CI are given in Table 2.
P2 and P3 showed a significantly smaller TEWL than
the reference product R, whereas no difference was de-
tected between P1 and R. P2 and P3 also showed a sig-
nificantly smaller TEWL than P1. No difference was
detected between P2 and P3.
Secondary endpoints
The mean results of the post-intervention corneometry
measurements were 49.7; 95 %-CI: 40.7–58.6 after P1,
45.4; 95 %-CI: 36.9–53.9 after P2, 64.3; 95 %-CI; 55.3–
73.2 after P3, and 48.9; 95 %-CI: 39.6–58.1 after R; test
of difference between agents P = 0.005. P3 showed a sig-
nificantly larger corneometry than the reference product
R (15.40; 95 %-CI: 4.09–26.70; P = 0.0087), whereas no
differences were detected between P1 and R or between P2
and R (0.81; 95 %-CI: −10.62–12.23; P = 0.89, and −3.50;
95 %-CI: −14.67–7.66; P = 0.53, respectively. P3 also
showed a significantly larger corneometry than P1 and P2
(14.59; 95 %-CI: 3.53–25.65; P = 0.011, and 18.90; 95 %-CI:
8.23–29.57; P = 0.0009, respectively. No difference was
detected between P1 and P2 (4.31; 95 %-CI: −6.33–
14.95; P = 0.42).
The skin status score was (palmar, median, range) 0.75
(0–2.0) after P1, 0 (0–1.5) after P2, 1.0 (0–3.0) after P3
and 0.5 (0–1.0) after R and (dorsal, median, range) 0.5
(0–2.0) after P1, 0 (0–3.0) after P2, 1 (0–2.0) after P3,
and 0.5 (0–1.5) after R.
Subjective satisfaction after application of the agents is
shown in Table 3. The overall impression was positive in
5 % of the subjects after P1, in 60 % after P2, in 17 %
after P3 and 0 % after R. In general, P2 showed the best
results for all the aspects covered, except smell.
The percentage of subjects experiencing at least one
AE related to application of the agents was 86 % (18/21)
for P1, 25 % (5/20) for P2, 89 % (16/18) for P3, and 44 %
(8/18) with R. The majority of AE were skin reactions
and were classified as of mild severity. The number of
patients experiencing a related AE of at least moderate
severity was 3 (14 %) for P1, 0 for P2, 1 (6 %) for P3, and
0 for R. No serious AE were observed.
Discussion
Hand disinfection with an alcohol-based hand rub is the
most important measure in infection control. Many as-
pects influencing hand hygiene compliance have been
identified, and it is well accepted that skin compatibility
plays an important role [8].
This is particularly evident for norovirus infections.
These viruses are highly transmissible and hand hygiene
compliance is essential to prevent and manage out-
breaks. Since non-enveloped viruses are typically highly
resistant to disinfectants, special formulations for hand
rubs are indicated. Activity against non-enveloped vi-
ruses such as noro- and adenovirus is based either on a
high concentration of ethanol as active ingredient or
supplementation with phosphoric acid. However, these
special formulations may impair skin tolerability and im-
pact negatively on healthcare workers’ compliance with
hand hygiene.
Because of the paucity of data investigating user ac-
ceptance of hand hygiene preparations, the objective of
this clinical trial was to evaluate the safety and tolerabil-
ity of regular use of different virucidal hand rubs within
the scope of post-marketing surveillance [9]. Furthermore,
to examine to what extent different virucidal compositions
Table 1 TEWL—by agent and intervention period (safety population, n = 22)
Agent
P1 P2 P3 R
Intervention period n Mean SD n Mean SD n Mean SD n Mean SD
1 5 21.26 4.92 6 19.25 6.17 4 13.93 3.39 4 26.93 5.07
2 5 17.92 2.63 5 19.94 9.41 6 15.48 3.08 4 23.98 6.39
3 3 28.03 12.99 4 13.40 2.72 3 20.67 1.33 5 23.74 8.20
4 5 24.08 3.26 5 13.02 2.11 5 17.08 5.09 4 21.50 6.95
P1 = Ethanol (100 %) 45 g, 1-Propanol (Ph.Eur.) 18 g (Softa-Man® acute, B. Braun Melsungen AG), P2 = Ethanol (99 %) 95 g (Sterillium® virugard, Bode Chemie
Hamburg GmbH), and, P3 = Ethanol (96 %) 57,6 g, 1-Propanol (Ph.Eur.) 10 g (Manorapid® Synergy, Antiseptica GmbH) , R (reference product) = Ethanol (100 %)
45 g, 1-Propanol (Ph.Eur.) 18 g (Softa-Man® pure, B. Braun Melsungen AG), n = number, SD = standard deviation
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(e.g. high ethanol concentration versus phosphoric acid)
offer good skin compatibility and user acceptance.
Because there was no knowledge of the differences to
be expected regarding the safety and tolerability of the
investigational products, a pilot study with a crossover
design was planned with a manageable number of sub-
jects that took into consideration potential demographic
differences and the possible external influence of time
(e.g. influence of cold weather on the skin) but
simulating an as near-to-real-life scenario as possible. To
objectively characterize skin compatibility, TEWL was
assessed as a primary and corneometry as a secondary
outcome. Both parameters quantitatively describe the
barrier function of the skin and have been well estab-
lished in investigations and clinical trials on topical
preparations and cosmetics [10].
Analysis of TEWL after the intervention period re-
vealed significantly lower TEWL for P2 and P3 as com-
pared to the reference product and P1. These results
suggest a better skin barrier function after application of
P2 and P3. After application of P3, corneometry was sig-
nificantly higher compared to the reference product,
which again indicates superior skin barrier function.
However, this effect was not seen for P2, where corneo-
metry did not differ from P1 or the reference product.
Skin status score was highest after application of P3
and P1. These preparations were also rated worst by the
volunteers. However, remarkably, the reference product
was not rated very well either. The results indicate poor
skin compatibility and impaired user acceptance, espe-
cially for those products containing phosphoric acid as
supplemental ingredient against non-enveloped viruses.
Since the study was blinded, it was not possible to
consider specific application times with respect to viru-
cidal activity. Had the application times tested for viru-
cidal activity specified by the manufacturers been
observed, P2 would have had to have been rubbed in
twice as long (2 min) as P1 and P3 (1 min each), mean-
ing double the volume would have been applied, which
hypothetically might have increased the interactions of
P2 with the skin.
From a mechanistic point of view, preparations that
are active against non-enveloped viruses are required to
damage viral proteins. This leads to a conflict of aims,
because damage can also be caused to surface proteins
of the skin and result in AEs. The number of AEs was
higher than expected for all the preparations tested. Due
to the high number of AEs, only 14 out of 22 patients
completed all the intervention periods. Most of the AEs
were classified as related to agent and of mild severity.
In assessing the large number of AEs, it should be
considered that in this investigation application of the
Table 3 Results of subject questionnaire—by agent (safety
population, n = 22)
Agent
P1 P2 P3 R
Aspect Assessment n % n % n % n %
Smell during
application
Pleasant 3 14.3 3 15.0 6 33.3 0 0.0
Neutral 11 52.4 7 35.0 11 61.1 10 58.8
Unpleasant 7 33.3 10 50.0 1 5.6 7 41.2
Missing 1 2 4 5
Skin feeling after
application
Optimal 3 15.0 13 65.0 4 22.2 3 18.8
Not
optimal
17 85.0 7 35.0 14 77.8 13 81.2
Missing 2 2 4 6
Sense directly after
application
Positive 4 19.0 12 60.0 3 16.7 1 5.9
Neutral 6 28.6 5 25.0 4 22.2 7 41.2
Negative 11 52.4 3 15.0 11 61.1 9 52.9
Missing 1 2 4 5
Sense while longer
application
Positive 1 4.8 11 55.0 1 5.6 1 5.9
Neutral 4 19.0 6 30.0 2 11.1 4 23.5
Negative 16 76.2 3 15.0 15 83.3 12 70.6
Missing 1 2 4 5
Overall impression
of agent
Positive 1 4.8 12 60.0 3 16.7 0 0.0
Neutral 8 38.1 6 30.0 4 22.2 9 52.9
Negative 12 57.1 2 10.0 11 61.1 8 47.1
Missing 1 2 4 5
Like to use agent
in the future
No 13 61.9 4 20.0 10 55.6 8 47.1
Yes 3 14.3 10 50.0 3 16.7 0 0.0
Undecided 5 23.8 6 30.0 5 27.8 9 52.9
Missing 1 2 4 5
Table 2 Results of TEWL measurements. Differences between agents (safety population, n = 22)
Difference to agent
P2 P3 R
Agent Differ-ence 95 %-CI P Difference 95 %-CI P Difference 95 %-CI P
P1 6.16 2.54–9.79 0.0013 6.14 2.38–9.89 0.002 −1.54 −5.33 - 2.26 0.42
P2 - - - −0.03 −3.69 - 3.64 0.99 −7.70 −11.45 - −2.96 0.0001
P3 - - - - - - −7.67 −11.45 - − 3.90 0.0002
P1 = Ethanol (100 %) 45 g, 1-Propanol (Ph.Eur.) 18 g (Softa-Man® acute, B. Braun Melsungen AG), P2 = Ethanol (99 %) 95 g (Sterillium® virugard, Bode Chemie
Hamburg GmbH), and, P3 = Ethanol (96 %) 57,6 g, 1-Propanol (Ph.Eur.) 10 g (Manorapid® Synergy, Antiseptica GmbH, R (reference product) = Ethanol (100 %) 45 g,
1-Propanol (Ph.Eur.) 18 g (Softa-Man® pure, B. Braun Melsungen AG)
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hand rubs (90 mL) differed to clinical practice in that it
took place within a condensed period of time (90 min).
Mechanical effects caused by constant rubbing must
therefore also be considered to play an important role in
the aetiology of the AEs.
Comparing the results from TEWL and corneometry
measurements on the one hand, and the clinical skin
score and AEs on the other, the data from this trial ap-
pear to be inconsistent. P3, for example, showed low
TEWL, suggesting fair skin barrier function but high
skin status score and a high number of AEs, which indi-
cates impaired skin compatibility. From this we conclude
that the skin barrier function could not be assessed reli-
ably within the trial setting. These parameters might
have been influenced by non-volatile compounds con-
tained in the investigational products, especially taking
into account that in our study rub application took place
within a condensed period. Thus, unlike the clinical set-
ting, where opportunities for hand disinfection are
present over the whole shift, and the hands have the
chance to dry in between applications, in our trial the
test preparations accumulated on the skin. The theory
that accumulation of non-volatile compounds con-
stricted reliable TEWL analysis was supported by the
fact that the values in P1 and the reference product were
comparable, since apart from supplementation of P1
with phosphoric acid the composition of the prepara-
tions was identical.
What conclusions can be drawn from these results
with regard to optimizing the study design of future tri-
als? Application of the test preparations could take place
over a longer period of time. However, extending single
interventions puts in question the feasibility of the study.
Another option would be to extend the period between
intervention end and assessment of the skin barrier.
What conclusions can be drawn from the study with
regard to the investigational products? We conclude that
all the preparations can be improved with regard to skin
compatibility and user acceptance. Evaluation of the skin
status score and the AEs suggests that preparations con-
taining phosphoric acid are likely to result in reduced
skin compatibility and user acceptance despite their
well-documented in-vitro activity against non-enveloped
viruses. In summary, this trial shows that there is room
for improvement with regard to study design and out-
come; it also provides essential information on the skin
compatibility of different virucidal hand rubs.
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